<DOC>
	<DOCNO>NCT01818492</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability efficacy new drug aim control disease activity patient diagnose primary haemophagocytic lymphohistiocytosis . The new drug administer first-line therapy , patient previously treat current standard care , give patient either fail unable tolerate current standard care . Administration top glucocorticosteroid , usually part current recommend treatment .</brief_summary>
	<brief_title>A Study Investigate Safety Efficacy Anti-IFNγ mAb Children Affected Primary Haemophagocytic Lymphohistiocytosis</brief_title>
	<detailed_description />
	<mesh_term>Lymphohistiocytosis , Hemophagocytic</mesh_term>
	<criteria>Gender : male female Age : include 18 year diagnosis Haemophagocytic Lymphohistiocytosis Primary HLH patient Patient ( ≥ 18 year old ) , patient 's legal representative ( ) must sign informed consent Diagnosis secondary Haemophagocytic Lymphohistiocytosis consequent proven rheumatic neoplastic disease . Body weight &lt; 3 kg . Patients treat biologics within specific timeframe Active Mycobacteria , Histoplasma Capsulatum , Shigella , Salmonella , Campylobacter Leishmania infection . Presence malignancy . Concomitant disease malformation severely affect cardiovascular , pulmonary , liver renal function</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>